Immunoregulatory factors in multiple sclerosis patients during and after pregnancy: relevance of natural killer cells
Open Access
- 6 December 2007
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical and Experimental Immunology
- Vol. 151 (2), 235-243
- https://doi.org/10.1111/j.1365-2249.2007.03555.x
Abstract
Multiple sclerosis (MS) ameliorates typically during pregnancy but after the delivery the relapse rate often increases. Our study was conducted to understand the immunoregulatory mechanisms accompanying this phenomenon. MS patients were followed-up prospectively during pregnancy and 6 months postpartum, with immunological characterization of the peripheral blood. Groups of age- and parity-matched healthy pregnant women, and age- and sex-matched non-pregnant women and non-pregnant MS patients were studied as controls. In our patient cohort, the annualized relapse rate was 1·0 ± 1·0 relapses/woman/year (mean ± standard deviation) during the year before pregnancy, but dropped to 0·2 ± 0·9 during the third trimester (P = 0·02). After the delivery the relapse rate increased again to 1·4 ± 1·9 (1–3 months postpartum versus third trimester P = 0·003). While percentages of peripheral blood CD3, CD4, CD8 and CD19 immune cell subsets were unchanged over the observation period, reduced disease activity during the last trimester was associated with a significant increase in the percentage of circulating CD56bright natural killer (NK) cells. Simultaneously, the proportion of circulating CD56dim NK cells was clearly reduced. No alteration was noted in CD4+ CD25high forkhead box P3+ regulatory T cells. Production of interferon-gamma by peripheral blood lymphocytes was down-regulated significantly during pregnancy in comparison to the postpartum period, resulting in an increased T helper type 2 (Th2) : Th1 ratio during pregnancy. In conclusion, pregnant state in MS patients is characterized by an increase in the percentage of CD56bright NK cells and by enhanced Th2 type cytokine secretion. Our findings suggest a potential role for CD56bright regulatory NK cells in the control of autoimmune inflammation during pregnancy in MS.Keywords
This publication has 45 references indexed in Scilit:
- Daclizumab phase II trial in relapsing and remitting multiple sclerosisNeurology, 2007
- Expansion of CD56Bright natural killer cells in the peripheral blood of multiple sclerosis patients treated with interferon-betaNeurological Sciences, 2007
- Increased frequency of CD4+ CD25+ regulatory T cells in the cerebrospinal fluid but not in the blood of multiple sclerosis patientsClinical and Experimental Immunology, 2007
- Regulatory CD56brightnatural killer cells mediate immunomodulatory effects of IL-2Rα-targeted therapy (daclizumab) in multiple sclerosisProceedings of the National Academy of Sciences, 2006
- Frequency of blood CX3CR1‐positive natural killer cells correlates with disease activity in multiple sclerosis patientsThe FASEB Journal, 2005
- T Lymphocytes Do Not Directly Mediate the Protective Effect of Estrogen on Experimental Autoimmune EncephalomyelitisThe American Journal of Pathology, 2004
- Shifts in the TH1/TH2 Balance during Human Pregnancy Correlate with Apoptotic ChangesBiochemical and Biophysical Research Communications, 1998
- Bidirectional cytokine interactions in the maternal-fetal relationship: is successful pregnancy a TH2 phenomenon?Immunology Today, 1993
- Pregnancy and Rheumatoid Arthritis: An OverviewAmerican Journal of Reproductive Immunology, 1992
- Rating neurologic impairment in multiple sclerosisNeurology, 1983